Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $718.95 million for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $718.95M | +8.6% |
| 2024 | $661.82M | +8.9% |
| 2023 | $607.52M | -8.9% |
| 2022 | $667.24M | +15.1% |
| 2021 | $579.77M | +11.4% |
| 2020 | $520.40M | +32.5% |
| 2019 | $392.75M | -3.9% |
| 2018 | $408.90M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $192.10M | +9.3% | +16.1% |
| June 30, 2025 | $165.45M | -1.7% | +10.4% |
| March 31, 2025 | $149.82M | +4.3% | -14.7% |
| September 30, 2024 | $175.69M | +14.2% | +4.4% |
| June 30, 2024 | $168.32M | +24.2% | +17.2% |
| March 31, 2024 | $143.64M | -6.6% | -6.7% |
| September 30, 2023 | $153.88M | -13.2% | +13.5% |
| June 30, 2023 | $135.56M | -20.3% | -11.8% |
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +8.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s revenue (asc 606) has grown by 75.8% (from $408.90 million to $718.95 million).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: